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Abstract
We determ ined the molecular basis of cystathionine (3-syn­
thase (CBS) deficiency in a partially pyridoxine-responsive 
homocystinuria patient. Direct sequencing of the entire 
CBS cDNA revealed the presence of a homozygous G 133flA 
transition. This m utation causes an  am ino acid change from  
aspartic acid to asparagine (D444N) in the  regulatory do­
m ain of the protein and abolishes a  T aqI restriction site at 
D N A  level. Despite the homozygous m utation , CBS activi­
ties in  extracts of cultured fibroblasts of this patien t were 
not in the homozygous but in the heterozygous range. F u r­
thermore, we observed no stim ulation o f CBS activity by 
S-adenosylmethionine, contrary to a threefold stim ulation 
in control fibroblast extract. The m uta tion  was in troduced 
in an  E. coli expression system an d  CBS activities were 
measured after addition of different S-adenosylm ethionine 
concentrations (0-200 jiM). Again, we observed a defective 
stimulation of CBS activity by S-adenosylm ethionine in the  
m utated  construct, whereas the norm al construct showed a 
threefold stim ulation in activity. These data  suggest th a t  
this D444N m utation  interferes in  S-adenosylm ethionine 
regulation of CBS. Furtherm ore, it indicates the im portance 
o f S-adenosylmethionine regulation o f the transsulfuration  
pathw ay in homocysteine homeostasis in hum ans. (J. Clin. 
In v es t  1996. 98:285-289.) Key words: homocysteine • cys­
tathionine (3-synthase deficiency * genetic m utation  • in 
vitro expression • methionine
Introduction
Homocystinuria due to cystathionine (3-synthase (CBS ,1 
L-serine hydro-lyase [adding homocysteine], EC 4.2.1.22) defi-
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ciency is an inborn error of methionine metabolism. CBS-defi- 
ciency is inherited as an autosomal recessive trait and is clini­
cally characterized by premature arteriosclerosis and thrombosis, 
ectopia lentis, skeletal abnormalities, and m ental retardation 
0 . 2 ).
In a large international survey of 629 homocystinuria pa­
tients, Mudd et al. (3) showed that about 50% of these patients 
were considered pyridoxine responsive, i.e., a large decrease in 
homocysteine concentrations was obtained upon administra­
tion of pharmacological doses of pyridoxine (vitamin B 6 ), the 
precursor of the co-factor for CBS.
CBS catalyzes the condensation of homocysteine and 
serine to cystathionine, an irreversible step in the transsulfura- 
tion pathway. This catalytic active enzyme consists of four 
identical subunits. T he C B S  gene has been m apped to the sub- 
telomeric segment of chromosome 21: 2 iq22.3 (4) and encodes 
a subunit of 63 kD.
Several imitations have been reported  in the human C B S  
cD N A  (5-7), of which most were screened for pathogenicity in 
a bacterial or yeast expression system (8 ,9). T he mutations de­
scribed so far, are located in the catalytic domain of the pro­
tein (amino acids 1 to 418; J.P. Kraus, unpublished results), 
with some clusters of mutations in exon 3 and 8 (10). No m uta­
tions have been reported in the  regulatory domain of this pro­
tein.
S-Adenosylmethionine (A doM et), an intermediate in the 
conversion of methionine to homocysteine, is the methyl do­
nor in various transmethylation reactions including nucleic ac­
ids, neurotransmitters, phospholipids, and hormones. It is an 
im portant regulator of homocysteine/methionine metabolism 
(11, 12), by stimulating CBS activity about threefold (13) and 
decreasing the formation of 5-m ethylenetetrahydrofolate by 
inhibition of m ethylenetetrahydrofolate reductase (M THFR). 
The result of elevated A doM et levels is a decreased remethy- 
lation of homocysteine to m ethionine and an enhanced clear­
ance of homocysteine via the transsulfuration pathway.
In this report, we describe a homocystinuria patient with 
severely elevated homocysteine concentrations, but with CBS 
activities in cultured fibroblasts in the heterozygous range. 
D N A  analysis revealed a novel m utation in the regulatory do­
main of the CBS protein. We were able to correlate this m uta­
tion to a defective regulation of the CBS protein  by A doM et in 
both fibroblasts and an E . coli expression system, which pro­
vides evidence for the im portant regulatory function of 
A doM et in homocysteine metabolism.
Methods
Patient. The patient is a woman, now 20 y of age, who had been ad­
mitted to the hospital at the age of nine years because of psychomo- 
toric retardation and marfanoid features such as excessive height,
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dolichostenomelia, and arachnodactyly. The diagnosis homozygous 
homocystinuria has been made then, and since she is treated with a 
combination of pyridoxine (vitamin B6, 500-750 mg daily), folic acid 
(5 mg daily), and betaine (6 grams daily). A t present time, i.e., 11 y af­
ter diagnosing and start of therapy, she is in a very good physical con­
dition and her intellectual development has reached an average level. 
Her length is 182 cm and weight 75 kg. She has not any physical com­
plaint. Ectopia lentis, osteoporosis, and vascular complications did 
not occur until now.
Biochemical analysis, Determination of homocystine, homocys- 
teine-cysteine mixed disulphide and methionine in serum of the pa­
tient was performed as described earlier by us (14). The amount of 
nonprolein-bound homocysteine was calculated as twice the concen­
tration of homocystine plus the concentration of the homocysteine- 
cysteine mixed disulphide. Total plasma homocysteine concentra­
tions, consisting of the total amount of protein and nonprotein-bound 
homocysteine, of a sister were determined according to Te Poele- 
Pothoff et al. (15).
CBS activities in extracts of cultured skin fibroblasts were deter­
mined in the absence and presence of 1 mM pyridoxal 5 '-phosphate 
(PLP) or different concentrations of AdoMet, essentially according 
to Engbersen et al. (16). Activities are expressed in nmol cystathionine 
formed per mg protein per hour at 37°C.
Methylenetetrahydrofolate reductase (MTHFR) activity was 
measured in isolated lymphocytes (16) in the absence and presence of 
75 or 400 AdoMet, and in cultured fibroblasts (17). The specific 
MTHFR activity is expressed in nmol formaldehyde formed per mg 
protein per hour. Protein concentrations were determined as de­
scribed by Lowry et al. (18). Folate and vitamin B12 concentrations 
were determined in heparinized plasma by routine hospital assays.
Mutation analysis. Genomic DNA was isolated from peripheral 
blood leukocytes according to a protocol by Miller et al. (19). Total 
RNA was extracted from cultured fibroblasts (20) and stored as an 
ethanol precipitate at -80°C. A 5 ;xg sample of RNA was reverse 
transcribed to cDNA in 1 h at 42°C with 200 units of Superscript II re­
verse transcriptase (Life Technologies, Breda, The Netherlands), us­
ing oligo(dT) and random hexamer primers. 1 /xl of this first-strand 
cDNA was subjected to PCR amplification. The oligonucleotides 
used were described elsewhere (7). These amplifications were carried 
out in a total volume of 100 jud, containing 100 ng forward and reverse 
primer, 200 pJVl each dNTP, 10 mM Tris-HCl pH 8.3,50 mM KC1,1.5 
mM MgCl2, 0.01% gelatin and 1 unit 7'aq polymerase (Life Technolo­
gies, Breda, The Netherlands). Amplification parameters were as fol­
lows: 35 cycles of 92°C/60 s (denaturation), 52-58°C/60 s (annealing) 
and 72°C/90 s (extension). The cycles were preceded by an initial de­
naturation step of 5 min at 95°C and were followed by a final exten­
sion of 7 min at 72°C.
By PCR, we generated three overlapping fragments which cov­
ered the entire coding region. Direct sequencing of these products 
was performed using the Taq Dye Deoxy™ Terminator Cycle Se­
quencing Kit according to the manufacturer’s recommendations (Ap­
plied Biosystems, Forster City, CA). The dye-labeled sequencing 
products were purified by phenol/chloroform extraction and ethanol 
precipitation at room temperature. The pellets were washed in 70% 
ethanol, solubilized in loading buffer (96% deionized formamide, 20 
mM EDTA, pH 8.0, dextran blue) and electrophoresed in a 6% poly­
acrylamide/8 M urea sequencing gel on a ABI 373A DNA sequencer. 
All PCR fragments were sequenced on both strands.
Genomic D N A  amplification. To confirm the mutation at the ge­
nomic DNA level, a fragment consisting of exon 11, intron 11 and 
exon 12 was amplified in the same PCR buffer as described above, us­
ing forward primer 5' -G ACC A A GTTCCTG AGCG A C A G G TG -3 ' 
(cDNA 1146-1169) and reverse primer 5'-CCCGCCTCATCCAC- 
CACGG-3' (cDNA 1358-1340). Amplification conditions were as 
follows: 5 min initial denaturation at 95°C, 35 cycles of 92°C/60 s, 
59°C/60 s and 72°C/45 s, followed by a final extension of 7 min at 
72°C. TaqI restriction enzyme analysis was performed according to 
the recommendations of the manufacturer (Life Technologies,
Breda, The Netherlands). Restriction fragments were resolved in a 
15% polyacrylamide gel containing 5% glycerol. Ethidium bromide 
staining was used to visualize the restriction fragments.
Cloning and expression o f  the mutation. The cDNA fragment con­
taining the mutation was amplified by PCR and subcloned into an 
expression cartridge derived from pHCS3, using BstXI and Kpnl, as 
described extensively (8, 21). E . coli JM109 cells were transformed 
and recombinants were selected by PCR and restriction enzyme anal­
ysis. The integrity of the mutated clone was established by sequencing 
analysis. Expression of the CBS  cDNA was induced by IPTG addi­
tion (21) and the CBS enzyme assay (16) was performed without ad­
dition of BSA to the incubation mixture. Cystathionine (Sigma, Am­
sterdam, The Netherlands) was added to a final concentration of
2 mM.
Results
Biochemical analysis. Hyperhomocysteinemia and hyperme- 
thioninemia were observed in our patient when compared to 
controls (Table I). Daily administration of 500 mg pyridoxine 
for six weeks resulted in only a minor reduction of homocys­
teine levels of ^ 3 0 % .  Additional administration of folic acid 
(5 mg daily, for 6 wk) and later on also of betaine (6 grams 
daily, for 6 wk) resulted in a marked decrease in homocys­
teine, however homocysteine was still elevated compared to 
controls (Table I). Therapy left methionine concentrations vir­
tually unchanged. In her sister, total plasma homocysteine con­
centration (protein plus nonprotein-bound) was elevated in 
fasting state (26 fimol/liter; reference values: 6-15 fjimol/liter) 
and after a methionine-loading test (72 fjimol/Iiter; reference 
values: 18-51 ¡¿mol/liter).
Folate concentration prior to treatment was 10 nmol/liter 
(control values: 5 .5 ^ 0  nmol/liter) and vitamin B 12 concentra­
tion was 180 pmol/liter (control values: 150-380 pmol/liter).
Specific M TH FR activity was normal in isolated lympho­
cytes of our patient (12.6, reference values: 9.1-23.9 nmol 
CH20 /m g  protein.h; n  =  18) as well as in cultured fibroblasts 
(6.2, reference values: 4.9-10.0 nmol CH20/m g protein.h; 
n — 6 ). In isolated lymphocytes, we found the same inhibition 
by AdoM et as observed in control lymphocytes (data not 
shown). She was found to be heterozygous for the previously 
described 677 C—>T transition in the M THFR gene (22).
Extracts of cultured fibroblasts were assayed for CBS activ­
ity in the presence and absence of 1 mM PLP, as shown in Ta-
Table L Fasting Serum Levels o f  Nonprotein-bound 
Homocysteine and Methionine at Base-line and Duving 
Therapy, at the Patient's Age o f  Nine Years
Therapy
Base-line
Pyridoxine + Folic acid + Betaine 
(500 mg daily) (5 mg daily) (6 grams daily)
Patient HCy*: 178 
Met: 83
HCy: 121 
Met: 79
HCy: 62 
Met: 80
HCy: 18 
Met: 69
Controls
(premenopausal)
HCy: 0.2-2.6 
Met: 16-38
*HCy refers to the amount of nonprotein-bound homocysteine (in 
jxmol/liter), and is calculated as twice the concentration of homocystine 
plus the concentration of homocysteine-cysteine mixed disulphide. Met, 
methionine.
286 Kluijtmans et al
Table II. CBS Activities in Extracts o f  Cultured Fibroblasts
-PLP 4- PLP
I m M
Controls (n — 12) 2.3-18.2 4.0--22.3
Obligate heterozygotes (n =  14) 0.17-2.4 0.39--5.4
Homozygotes (n  =  14) o 1 o • 0 --1.6
Patient 1.7 2,,6
Activities are expressed in nmol cystathionine formed per mg protein 
per hour. P L P , pyridoxal 5'~phosphate. I 2 3 4 5
ble II. Both measurements show CBS activities in the het­
erozygous range which is in contrast to the severely elevated 
homocysteine levels observed in this patient, D N A  analysis of 
the CBS  cDNA was performed to explore the genetic basis un­
derlying this contradiction.
D N A  analysis. We synthesized three sets of oligonucle­
otides which enabled us to amplify overlapping fragments cov­
ering the entire CBS  cDNA. The PCR fragments generated 
were all of the expected size, suggesting the existence of point 
mutations rather than small deletions, insertions or splice error 
mutations in the cDNA of this patient.
Direct sequencing of the entire coding region revealed a 
novel homozygous G 133oA missense mutation. No other se­
quence aberrations could be detected in the CBS  cDNA. This 
mutation is expected to cause an amino acid change from as­
partic acid (GAC) to asparagine (AAC) at position 444 of the 
mature protein (D444N), i.e., a negatively charged amino acid 
is replaced with a neutral one. The mutation abolished a TaqI 
restriction site which was used to confirm the mutation at the 
genomic D N A  level. Screening of both parents and an unaf­
fected sister revealed their heterozygous state for this transi­
tion (Fig. 1). We were unable to detect this mutation among 14 
other Dutch homozygotes for CBS deficiency, indicating that 
this transition is rare among Dutch homocystinurics. The 
D444N substitution was not observed in 80 control chromo­
somes.
In vitro expression and AdoMet regulation. The pathogenic 
nature of the G1330A transition was investigated both in cul­
tured fibroblasts and in an E. coli expression system. CBS as­
says in extracts of cultured fibroblasts were performed after 
addition of different AdoM et concentrations to the incubation 
mixture. As shown in Fig. 2 , AdoM et stimulates CBS activity 
about threefold in control fibroblasts, contrary to virtually no 
stimulation observed in fibroblast extracts of the patient.
We cloned the cDNA fragment, containing the G1330A 
transition, into an expression cartridge to restore the CBS  
cDNA in plasmid pHCS3. The presence of the mutation and 
the absence of artifacts introduced by PCR were confirmed by 
sequence analysis of the cloned fragment and its cloning sites 
(data not shown). Cell lysates were analyzed for CBS activity 
in the presence of different concentrations of AdoM et (0-200 
[xM; Fig, 3). This figure clearly demonstrates that CBS activity 
in the mutant is indistinguishable from the control when m ea­
sured in the absence of AdoMet. AdoM et, however, is unable 
to stimulate the CBS protein with the D444N substitution to 
the same extent as the CBS protein translated from the control 
construct, which is stimulated threefold.
54 bp
30 bp 
24 bp
F ig u re  1. Pedigree of the family. A  genomic D N A  fragment was am­
plified by PCR, screened for the mutation by TaqI restriction enzyme 
analysis and subsequently electrophoresed in a 15% polyacrylamide 
gel, The mutated allele yields one fragment of 54 bp, whereas the 
wild-type allele yields two fragments of 30 and 24 bp, respectively. A 
larger fragment of ^  500 bp, present in all samples, was cut off the 
photo for clarity. Lane h  healthy male control; lane 2: father; lane 3: 
mother; lane 4: patient; lane 5: sister.
Discussion
Severe hyperhomocysteinemia, as observed in our patient, 
may be caused by a homozygous deficiency in CBS or 
M THFR, two regulating enzymes in homocysteine m etabo­
lism. In  this study, we detected a novel G ^ A  (D444N) mis­
sense mutation in the regulatory dom ain of the CBS protein,
AdoMet concentration (jumol/L)
F ig u re  2, CBS activities in extracts of cultured fibroblasts of a healthy 
control and the patient in the presence of different concentrations of 
S-adenosylmethionine. Each point represents the mean of two inde­
pendent experiments.
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OjuM A d o M e t
25juM A d o M e t
5 0 jliM  A d o M e t
1 0 0 |iM  A d o M e t  
200/xM A d o M e t
C ontrol M u tan t
Figure 3. Regulation of CBS activity by S-adenosylmethionine in cell 
lysates of the E. coli expression system. Control denotes expression 
plasmid pHCS3 harboring the wild-type CBS cDNA sequence. Mu­
tant denotes the mutated plasmid pHCS3 containing the G I3;J„A tran­
sition. Each bar represents the mean of two independent experi­
ments.
which is associated with a defective regulation of the CBS pro­
tein by AdoMet.
Until now, about 18 mutations have been described in the 
CBS  gene in patients with homocystinuria due to CBS defi­
ciency (5-7). Some mutations seem ed to be rather unique to 
one family, while others, especially the I278T (21) and G307S 
(23), occur more frequently. All mutations described so far, 
are located in the NH2-terminal domain and are thought to in­
terfere in the catalytic activity of the enzyme.
In our patient, we detected an apparent mild D444N m uta­
tion in the regulatory dom ain of the CBS protein, implying a 
mild CBS deficiency. However, the clinical manifestations and 
the severe hyperhomocysteinemic status of the patient and the 
moderate hyperhomocysteinemia of the heterozygous sister, 
indicate that this mutation may interfere in a very important 
regulation of CBS activity.
In extracts of cultured fibroblasts, we observed an excep­
tionally high residual CBS activity for a homocystinuria pa­
tient compared to 14 other diagnosed CBS deficient patients 
(Table II). Homocystinuria patients described so far, exhibited 
dramatically decreased CBS activities in cultured fibroblasts. 
However, Uhlendorf, Bittles and their co-workers (24,25), de­
scribed each a homocystinuria patient with CBS activities in 
the heterozygous or low-normal range. They ascribed these 
findings to either a very mild homozygous CBS deficiency, or 
to a heterozygous deficiency with hepatic CBS activities un­
usually low for heterozygotes, which could lead to homocysti­
nuria. According to our data, those patients may be homozy­
gotes for CBS deficiency defective in CBS regulation.
Expression of the D444N m utation was performed in an 
E. coli expression system (8 , 21). CBS enzyme expressed in 
E. coli is indistinguishable from hum an CBS enzyme present 
in cultured fibroblasts. It is able to bind PLP, heme and 
A doM et and exhibits catalytic activity (2 1 , 26). Activities ob­
tained when expressing the m utant construct were equal to 
those observed in the control construct in the absence of 
AdoMet. Thus, the m utation has no pathogenic nature in the 
absence of A doM et in our in vitro expression system. Addition 
of A doM et to the incubation mixture reveals the pathogenic
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nature of the mutation: it interferes in the regulation of the 
CBS protein by AdoMet.
The E . coli expression with our mutant CBS construct 
showed a normal basal activity, contrary to fibroblasts, in 
which we observed a reduced basal activity. However, the ef­
fect of a mutation on protein activity in cultured fibroblasts 
cannot be compared directly with its effect in E. coli. It is 
known that mutant polypeptides are degraded more rapidly in 
cultured fibroblasts than in E . coli, which has also been dem­
onstrated for mutant CBS subunits (21). The discrepancy ob­
served may depend on differences in protein catabolism be­
tween both systems, heme status (important in CBS function) 
and the concentration of stabilizing (co)-factors.
Although our experiments in the E . coli expression system 
show that this D444N mutation is causing a regulatory defect, 
we were unable to exclude a possible influence of the mutation 
on CBS activity in liver, the main site of homocysteine catabo­
lism. The mutation may also have an effect on protein synthe­
sis and/or turnover of CBS in liver affecting hepatic CBS activ­
ity and plasma homocysteine concentration in this patient. For 
ethical reasons we were unable to obtain a liver specimen to 
address this issue,
AdoMet is an allosteric regulator of the homocysteine flux 
through either the transsulfuration or remethylation pathway. 
Low levels of A doM et favor the conservation of the homocys- 
teine-skeleton of methionine, whereas high levels of AdoMet 
stimulate the irreversible conversion of homocysteine to cys­
tathionine in the transsulfur ation pathway (12). The disruption 
of this regulation of homocysteine metabolism may explain the 
severe hyperhomocysteinemia observed in our patient. Due to 
the homozygous G l330A transition in the CBS  gene, AdoMet is 
unable to stimulate CBS, so a surplus of homocysteine will not 
be degraded via the transsulfuration pathway. Furthermore, 
the elevated AdoM et levels will inhibit M TIiFR, resulting in 
an additional accumulation of homocysteine.
M THFR deficiency was excluded as a possible contributor 
to hyperhomocysteinemia. Specific M THFR activity in iso­
lated lymphocytes as well as in cultured fibroblasts of our pa­
tient was well within the reference range, excluding a major 
defect in MTHFR. Furthermore, regulation of MTHFR by 
AdoM et was found to be normal. The patient is heterozygous 
for the previously described 677C—>T transition in the 
M THFR gene. The prevalence of this heterozygous state in 
the Dutch population is ~  40% (27,28). In homozygous state, 
this mutation is associated with elevated homocysteine con­
centrations (22, 27, 28), especially in circumstances of low 
(normal) folate (29). Plasma homocysteine concentrations in 
heterozygotes however, do not differ significantly from those 
observed in wild-type individuals (22, 27-29). An interaction 
between lowered folate and plasma homocysteine has only 
been described in individuals with the homozygous mutant 
genotype and not in heterozygous individuals (29).
Comparison of the human CBS to the rat enzyme and sev­
eral homologous cysteine synthases from plants and bacteria 
(5), indicates an extensive homology in the NHz-terminal part 
of these proteins. This N H 2-terminal domain, encoded by exon 
1 to 12 , is believed to bind both substrates (homocysteine and 
serine), heme, and its cofactor PLP. The COOH-terminal do­
main of the CBS protein is only conserved in rat CBS (30) and 
partly in yeast CBS (9), in which also the aspartic acid-444 res­
idue is conserved, but is absent in O-acetylserine (thiol)-lyase 
(cysK) from E. coli (31). However, this latter enzyme, which
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shows 52% sequence similarity to hum an CBS, catalyzes the 
formation of cysteine from O-acetyl-L-serine and inorganic 
sulfide and not the homocysteine conversion into cystathionine 
in this organism. Although the enzymatic function is different, 
both enzymes, CBS, and cysK, condense serine and a sulfur 
containing compound to either cystathionine or cysteine.
Pathogenicity of the G 1330A mutation was ascertained by 
four different methods. First, we found no other mutations in 
the coding region of the CBS  gene, which could be responsible 
for the severely elevated homocysteine and methionine levels. 
Second, the mutation was absent in 80 control alleles, indicat­
ing that it is not a benign polymorphism. Third, the wild-type 
aspartic acid-444 residue is conserved in the evolution, which is 
evidence for functional relevance of this amino acid in the bio­
logical function of the protein. Fourth, we observed a defective 
regulation of CBS by AdoMet in extracts of cultured fibro­
blasts of this patient and in a prokaryotic expression system in 
which we introduced this mutation.
To our knowledge, this is the first report of a mutation in 
the regulatory domain of the CBS protein. W e have provided 
substantial evidence that the D444N substitution is a patho­
genic mutation and interferes in the normal regulation of the 
CBS protein by AdoMet, although a possible effect on CBS 
synthesis and turnover in liver could not be excluded. From a 
diagnostic point of view, we urge others to include an 
AdoM et-dependent enzyme assay in the diagnosis of h o ­
mocystinuria, because similar patients could be missed in the 
regular screening methods, which could lead to a false conclu­
sion regarding the origin of homocystinuria in such patients.
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